Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

Yair Lotan, Trinity Bivalacqua, Tracy Downs, William Huang, Jeffrey Jones, Ashish M. Kamat, Badrinath Konety, Per Uno Malmström, James McKiernan, Michael O’Donnell, Sanjay Patel, Kamal Pohar, Matthew Resnick, Alexander Sankin, Angela Smith, Gary Steinberg, Edouard Trabulsi, Michael Woods, Siamak Daneshmand

Research output: Contribution to journalReview article

Abstract

Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6% of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed.

Original languageEnglish (US)
JournalNature Reviews Urology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cystoscopy
Urinary Bladder Neoplasms
Light
Recurrence
5-aminolevulinic acid hexyl ester
Multicenter Studies
Neoplasms
Prospective Studies
Technology
Costs and Cost Analysis

ASJC Scopus subject areas

  • Urology

Cite this

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer : review of the clinical evidence and consensus statement on optimal use in the USA — update 2018. / Lotan, Yair; Bivalacqua, Trinity; Downs, Tracy; Huang, William; Jones, Jeffrey; Kamat, Ashish M.; Konety, Badrinath; Malmström, Per Uno; McKiernan, James; O’Donnell, Michael; Patel, Sanjay; Pohar, Kamal; Resnick, Matthew; Sankin, Alexander; Smith, Angela; Steinberg, Gary; Trabulsi, Edouard; Woods, Michael; Daneshmand, Siamak.

In: Nature Reviews Urology, 01.01.2019.

Research output: Contribution to journalReview article

Lotan, Y, Bivalacqua, T, Downs, T, Huang, W, Jones, J, Kamat, AM, Konety, B, Malmström, PU, McKiernan, J, O’Donnell, M, Patel, S, Pohar, K, Resnick, M, Sankin, A, Smith, A, Steinberg, G, Trabulsi, E, Woods, M & Daneshmand, S 2019, 'Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018', Nature Reviews Urology. https://doi.org/10.1038/s41585-019-0184-4
Lotan, Yair ; Bivalacqua, Trinity ; Downs, Tracy ; Huang, William ; Jones, Jeffrey ; Kamat, Ashish M. ; Konety, Badrinath ; Malmström, Per Uno ; McKiernan, James ; O’Donnell, Michael ; Patel, Sanjay ; Pohar, Kamal ; Resnick, Matthew ; Sankin, Alexander ; Smith, Angela ; Steinberg, Gary ; Trabulsi, Edouard ; Woods, Michael ; Daneshmand, Siamak. / Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer : review of the clinical evidence and consensus statement on optimal use in the USA — update 2018. In: Nature Reviews Urology. 2019.
@article{626f458e3a3b4277a786a00f1ac1026d,
title = "Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018",
abstract = "Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6{\%} of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed.",
author = "Yair Lotan and Trinity Bivalacqua and Tracy Downs and William Huang and Jeffrey Jones and Kamat, {Ashish M.} and Badrinath Konety and Malmstr{\"o}m, {Per Uno} and James McKiernan and Michael O’Donnell and Sanjay Patel and Kamal Pohar and Matthew Resnick and Alexander Sankin and Angela Smith and Gary Steinberg and Edouard Trabulsi and Michael Woods and Siamak Daneshmand",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41585-019-0184-4",
language = "English (US)",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer

T2 - review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

AU - Lotan, Yair

AU - Bivalacqua, Trinity

AU - Downs, Tracy

AU - Huang, William

AU - Jones, Jeffrey

AU - Kamat, Ashish M.

AU - Konety, Badrinath

AU - Malmström, Per Uno

AU - McKiernan, James

AU - O’Donnell, Michael

AU - Patel, Sanjay

AU - Pohar, Kamal

AU - Resnick, Matthew

AU - Sankin, Alexander

AU - Smith, Angela

AU - Steinberg, Gary

AU - Trabulsi, Edouard

AU - Woods, Michael

AU - Daneshmand, Siamak

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6% of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed.

AB - Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6% of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed.

UR - http://www.scopus.com/inward/record.url?scp=85064890868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064890868&partnerID=8YFLogxK

U2 - 10.1038/s41585-019-0184-4

DO - 10.1038/s41585-019-0184-4

M3 - Review article

C2 - 31019310

AN - SCOPUS:85064890868

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

ER -